Adjunctive treatment strategies for high-risk ocular melanoma

Sapna P. Patel; Dan S. Gombos

doi:10.2217/FMEB2013.13.35

Adjunctive treatment strategies for high-risk ocular melanoma

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Currently, the use of adjuvant therapy for uveal melanoma is a wide-open question. To begin to answer the question, we need to define our high-risk population perhaps more uniformly using only genetic testing, utilize appropriate targets and implement thoughtful trial design.

Original language	English (US)
Title of host publication	Ocular Melanoma
Subtitle of host publication	Advances in Diagnostic and Therapeutic Strategies
Publisher	Future Medicine Ltd.
Pages	160-167
Number of pages	8
ISBN (Electronic)	9781780844268
ISBN (Print)	9781780844282
DOIs	https://doi.org/10.2217/FMEB2013.13.35
State	Published - Jul 1 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.2217/FMEB2013.13.35

Cite this

@inbook{c7cdbf8d170042349f60aea63e74b72a,

title = "Adjunctive treatment strategies for high-risk ocular melanoma",

abstract = "Currently, the use of adjuvant therapy for uveal melanoma is a wide-open question. To begin to answer the question, we need to define our high-risk population perhaps more uniformly using only genetic testing, utilize appropriate targets and implement thoughtful trial design.",

author = "Patel, {Sapna P.} and Gombos, {Dan S.}",

year = "2014",

month = jul,

day = "1",

doi = "10.2217/FMEB2013.13.35",

language = "English (US)",

isbn = "9781780844282",

pages = "160--167",

booktitle = "Ocular Melanoma",

publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Adjunctive treatment strategies for high-risk ocular melanoma

AU - Patel, Sapna P.

AU - Gombos, Dan S.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Currently, the use of adjuvant therapy for uveal melanoma is a wide-open question. To begin to answer the question, we need to define our high-risk population perhaps more uniformly using only genetic testing, utilize appropriate targets and implement thoughtful trial design.

AB - Currently, the use of adjuvant therapy for uveal melanoma is a wide-open question. To begin to answer the question, we need to define our high-risk population perhaps more uniformly using only genetic testing, utilize appropriate targets and implement thoughtful trial design.

UR - http://www.scopus.com/inward/record.url?scp=84956781141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956781141&partnerID=8YFLogxK

U2 - 10.2217/FMEB2013.13.35

DO - 10.2217/FMEB2013.13.35

M3 - Chapter

AN - SCOPUS:84956781141

SN - 9781780844282

SP - 160

EP - 167

BT - Ocular Melanoma

PB - Future Medicine Ltd.

ER -

Adjunctive treatment strategies for high-risk ocular melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this